The INSIGHT-003 OS data is encouraging but comes from a small, investigator-initiated Phase I trial (N=51) and is not registrational. The TACTI-004 failure raises significant uncertainty about efti's efficacy in a larger, randomized setting. Traders should watch for the root cause analysis results in Q3 CY2026, which could determine whether efti has a viable path forward in NSCLC or other indications.
Price Chart
Executive Summary
Immutep reported mature overall survival data from the Phase I INSIGHT-003 trial in 1L non-squamous NSCLC, showing median OS of 30.9 months (N=51) vs. a 22.0-month historical benchmark, with no new safety signals. However, the update also disclosed that the Phase III TACTI-004 trial was discontinued after a futility analysis (ORR 42.9% efti arm vs. 55.1% control), and a root cause analysis is ongoing with results expected in Q3 CY2026. The positive INSIGHT-003 data is offset by the TACTI-004 failure, creating a mixed picture for efti's development path.
Key Facts
- INSIGHT-003 (N=51) showed mature median OS of 30.9 months in overall population and in TPS<50% subgroup, vs. 22.0-month historical benchmark (KEYNOTE-189).
- Approximately 92% of INSIGHT-003 patients had TPS<50% (no/low PD-L1 expression), a population with high unmet need.
- TACTI-004 Phase III trial was discontinued after a futility analysis: ORR 42.9% (efti arm) vs. 55.1% (control arm); efti did not show superiority in any TPS subgroup.
- Preliminary immune monitoring from TACTI-004 showed a different immune activation profile vs. prior efti studies; root cause analysis ongoing, results expected Q3 CY2026.
- No new safety signals in either trial since prior data cutoffs.
Financial Impact
No financial figures reported; the company is a clinical-stage biotech with no approved products or revenue.
Risk Factors
- TACTI-004 failure may indicate a fundamental efficacy issue with efti in 1L NSCLC, potentially limiting its commercial prospects.
- INSIGHT-003 is a small, single-arm, investigator-initiated trial; results may not replicate in larger, randomized registrational studies.
- Root cause analysis may not yield a clear explanation or actionable fix, prolonging development uncertainty.
- No revenue or near-term catalyst to commercialization; stock is highly sensitive to clinical trial outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-302281 |
| Document: d105704d6k.htm | 0001193125-26-302281 |
| Document: 0001193125-26-302281-index-headers.html | 0001193125-26-302281 |
| Document: 0001193125-26-302281-index.html | 0001193125-26-302281 |
| Document: 0001193125-26-302281.txt | 0001193125-26-302281 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 6-K | $0.3800 $4.65 | ▼ −1123.68% | ▼ −1123.77% | $4.54 (−1094.74%) |
Jul 14, 2026 11w ago | 6-K | $0.4328 $0.3933 | ▼ −9.13% | ▼ −11.62% | $4.54 (+948.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access